Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

Recruiting

Phase 1

Allogeneic T-cell TherapyStudy of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

Sponsor:

St. Jude Children's Research Hospital

Code:

NCT04881240

Conditions

Acute Lymphoblastic Leukemia, in Relapse

Acute Lymphoblastic Leukemia, Refractory

Pediatric ALL

Eligibility Criteria

Sex: All

Age: 0 - 21

Healthy Volunteers: Not accepted

Interventions

CD19-CAR(Mem) T-cells

Cyclophosphamide

Fludarabine

Mesna

CliniMACS

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by St. Jude Children's Research Hospital on 2025-01-17.